FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.
What happened
FDA inspected Pro-Optics in Palatine, Illinois, from March 3, 2026 through March 11, 2026, and reviewed its website. FDA found the firm changed polymers and colorants in its Tight Top and Flip Top contact lens cases without a new premarket notification, and lacked design and change-control records.
What FDA found
FDA says the contact lens cases are adulterated because the firm lacks an approved premarket approval or investigational device exemption.
section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)FDA says the firm did not notify FDA before commercially distributing changed devices, making them misbranded.
section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 C.F.R. 807.81(a)(3)(i)The firm changed polymers and colorants from those cleared under K875197, including adding uncleared colors, without FDA review.
21 C.F.R. 807.81(a)(3)(i)The firm had no documented design and development procedures or records.
ISO 13485:2016, Clause 7.3.1; 21 C.F.R. Part 820The firm did not document or evaluate the change from one contract manufacturer to another.
ISO 13485:2016, Clause 4.1.4; 21 C.F.R. Part 820
What FDA wants
FDA asks Pro-Optics to respond in writing within 15 business days with the specific steps taken to correct the violations, documentation of systemic fixes, and a timetable for any longer-term actions; if it believes products are not in violation, it must include reasoning and supporting information.
Who should pay attention
- distributors and retailers selling contact lens cases
- private-label brands sourcing molded device components
- device firms relying on 510(k) clearances and design-change records
This is a summary. Read the original letter on fda.gov.